The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.
 
Ruben A. Mesa
Honoraria - Abbvie; AOP Orphan Pharmaceuticals; BMS; Geron; Novartis; shire; Sierra Oncology
Consulting or Advisory Role - Baxalta; Galena Biopharma; Incyte; Novartis
Research Funding - Abbvie (Inst); Celgene (Inst); CTI (Inst); Genentech (Inst); Gilead Sciences (Inst); Imago Pharma (Inst); Incyte (Inst); NS Pharma (Inst); Pfizer (Inst); Pharmaessentia (Inst); Promedior (Inst)
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Incyte; Novartis; Pharmaessentia
 
Stacie Hudgens
Consulting or Advisory Role - Clinical Outcomes Solutions (Inst)
Research Funding - Clinical Outcomes Solutions (Inst)
 
Lysbeth Floden
Employment - Clinical Outcomes Solutions
Consulting or Advisory Role - Sierra Oncology
 
Jeanne Palmer
No Relationships to Disclose
 
Vikas Gupta
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; Novartis; Sierra Oncology
Consulting or Advisory Role - Celgene; Novartis; Roche; Sierra Oncology
Research Funding - Novartis (Inst)
 
Donal P. Mclornan
Honoraria - Celgene; Jazz Pharmaceuticals; Novartis
Speakers' Bureau - Celgene; Jazz Pharmaceuticals; Novartis
 
Mary Frances McMullin
Consulting or Advisory Role - Novartis
Speakers' Bureau - Celgene; Jazz Pharmaceuticals
 
Jean-Jacques Kiladjian
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; Bristol Myers Squibb Foundation; Novartis
 
Lynda M. Foltz
Honoraria - Novartis
Consulting or Advisory Role - Celgene
Research Funding - Constellation Pharmaceuticals; Incyte
 
Uwe Platzbecker
Honoraria - Celgene/Jazz
Consulting or Advisory Role - Celgene/Jazz
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019)
Travel, Accommodations, Expenses - Celgene
 
Maria Laura Fox
No Relationships to Disclose
 
Adam J. Mead
Honoraria - Celgene/Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Abbvie; Celgene/Bristol-Myers Squibb; CTI; Gilead Sciences; Novartis
Speakers' Bureau - Celgene/Bristol-Myers Squibb
Research Funding - Celgene/Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Celgene; Novartis
 
David M. Ross
Honoraria - Bristol-Myers Squibb; Celgene; Novartis
Consulting or Advisory Role - Keros Therapeutics
Research Funding - Bristol-Myers Squibb; Celgene; Novartis
 
Stephen T. Oh
Consulting or Advisory Role - Blueprint Medicines; Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Incyte; Kartos Therapeutics; Novartis; PharmaEssentia
Research Funding - Blueprint Medicines (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Gilead Sciences (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Sierra Oncology (Inst)
 
Andrew Perkins
Honoraria - Novartis
 
Michael F. Leahy
No Relationships to Disclose
 
Samineh Deheshi
Employment - Sierra Oncology
Stock and Other Ownership Interests - Sierra Oncology
 
Rafe Donahue
Employment - Sierra Oncology
Stock and Other Ownership Interests - Sierra Oncology
 
Barbara J. Klencke
Employment - Sierra Oncology
Leadership - Sierra Oncology
Stock and Other Ownership Interests - Sierra Oncology
 
Srdan Verstovsek
Consulting or Advisory Role - Celgene; Constellation Pharmaceuticals; Incyte; Novartis; Sierra Oncology
Research Funding - Blueprint Medicines; Celgene; CTI BioPharma Corp; Genentech; Gilead Sciences; Incyte; Novartis; NS Pharma; Promedior; Roche